Recursion expects to share Phase II data for REC-994 in the first half of 2025, through a publication, webinar, or presentation at a medical conference. By the end of this year, Recursion plans to ...
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...
Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback